| Literature DB >> 29566027 |
Sedigheh Gharbi1, Shahriar Khateri2, Mohammad Reza Soroush2, Mehdi Shamsara3, Parisa Naeli4, Ali Najafi5, Eberhard Korsching6, Seyed Javad Mowla4.
Abstract
Sulfur mustard is a vesicant chemical warfare agent, which has been used during Iraq-Iran-war. Many veterans and civilians still suffer from long-term complications of sulfur mustard exposure, especially in their lung. Although the lung lesions of these patients are similar to Chronic Obstructive Pulmonary Disease (COPD), there are some differences due to different etiology and clinical care. Less is known on the molecular mechanism of sulfur mustard patients and specific treatment options. microRNAs are master regulators of many biological pathways and proofed to be stable surrogate markers in body fluids. Based on that microRNA expression for serum samples of sulfur mustard patients were examined, to establish specific microRNA patterns as a basis for diagnostic use and insight into affected molecular pathways. Patients were categorized based on their long-term complications into three groups and microRNA serum levels were measured. The differentially regulated microRNAs and their corresponding gene targets were identified. Cell cycle arrest, ageing and TGF-beta signaling pathways showed up to be the most deregulated pathways. The candidate microRNA miR-143-3p could be validated on all individual patients. In a ROC analysis miR-143-3p turned out to be a suitable diagnostic biomarker in the mild and severe categories of patients. Further microRNAs which might own a link to the biology of the sulfur mustard patients are miR-365a-3p, miR-200a-3p, miR-663a. miR-148a-3p, which showed up only in a validation study, might be linked to the airway complications of the sulfur mustard patients. All the other candidate microRNAs do not directly link to COPD phenotype or lung complications. In summary the microRNA screening study characterizes several molecular differences in-between the clinical categories of the sulfur mustard exposure groups and established some useful microRNA biomarkers. qPCR raw data is available via the Gene Expression Omnibus https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110797.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29566027 PMCID: PMC5864010 DOI: 10.1371/journal.pone.0194530
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Patient cohort.
Participants were categorized into the four classes of normal, mild, moderate and severe based on the history of exposure to sulfur mustard, PFT and other clinical examinations. The samples of the screening study were randomly pooled into two biological replicates and measured.
Fig 2Comparative differential microRNA analysis workflow including sampling controls.
The panel (A) shows that two different analysis approaches were applied. On the left side the IPC and delta Ct method followed by linear model / Bayes based differential analysis was performed while on the right side a pure linear model / Bayes approach was used based on the results of the pilot analysis. The relevance of both approaches was tested by a resampling approach. The right branch was finally chosen and basis for the discussion. In panel (B) the results of all the alternative tests on either the normal-mild or the normal-severe comparisons are shown. The results on the right side indicate that in the normal-mild comparison 15 and in the normal-severe comparison 29 microRNAs are stable on a 5% significance level after applying the resampling control. The numbers on white background indicate the remaining candidates after the intersections were performed. The result denotes a good consistency between left and right procedure.
Fig 3Box plots of raw data microRNA expression values and controls.
On the x axis the different measurement groups for each experiment are shown: 'control' stands for reference genes including miR-103a-3p, miR-423-5p and miR-191-5p. 'control2' denotes non-miRNA coding reference genes. 'IPC' lists the inter plate calibrators. 'targets' comprises all the measured individual microRNAs. As can be seen in this figure the distribution of the target genes is nearly consistent in all tested samples even on the raw data level. The y axis denotes the Ct values.
Fig 4Overview on the density distributions.
The target microRNAs in the different patient`s groups show a very uniform distribution on the raw data level. The y axis denotes the normalized density, while the x axis shows the Ct values. Because of the smoothing effect of the density curves Ct values above 40 show up, which is artificial (maximum is 40).
Differential microRNAs (15) of the normal-mild group.
The values shown here are from the right part of the workflow in Fig 2. dCt: delta Ct, FC: fold change and sampling p: sampling p value which was finally considered.
| MicroRNA Name | dCt | FC | p value | sampling p | |
|---|---|---|---|---|---|
| 1 | hsa-miR-589-3p | 5.236 | 0.027 | 0.0021 | 0.0006 |
| 2 | hsa-miR-542-5p | 4.701 | 0.038 | 0.0022 | 0.0014 |
| 3 | hsa-miR-886-5p | 4.305 | 0.051 | 0.00446 | 0.0020 |
| 4 | hsa-miR-550-5p | 3.896 | 0.067 | 0.0055 | 0.0030 |
| 5 | hsa-miR-143-3p | -4.725 | 26.454 | 0.0070 | 0.0033 |
| 6 | hsa-miR-520d-5p | 3.311 | 0.101 | 0.0105 | 0.0051 |
| 7 | hsa-miR-329-3p | 3.416 | 0.094 | 0.0121 | 0.0057 |
| 8 | hsa-miR-654-5p | 3.101 | 0.117 | 0.0136 | 0.0088 |
| 9 | hsa-miR-509-3p | 3.310 | 0.101 | 0.0152 | 0.0104 |
| 10 | hsa-miR-185-3p | 3.425 | 0.093 | 0.0182 | 0.0130 |
| 11 | hsa-miR-510-5p | 2.961 | 0.128 | 0.0180 | 0.0137 |
| 12 | hsa-miR-301b-3p | 2.770 | 0.147 | 0.0250 | 0.0188 |
| 13 | hsa-miR-99a-5p | -2.949 | 7.722 | 0.0366 | 0.0335 |
| 14 | hsa-miR-202-3p | 2.466 | 0.181 | 0.0393 | 0.0358 |
| 15 | hsa-miR-184 | 2.431 | 0.185 | 0.0430 | 0.0384 |
Differential microRNAs (29) of the normal-severe group.
The values shown here are from the right part of the workflow in Fig 2. dCt: delta Ct, FC: fold change and sampling p: sampling p value which was finally considered.
| MicroRNA Name | dCt | FC | p value | sampling p | |
|---|---|---|---|---|---|
| 1 | hsa-miR-589-3p | 5.236 | 0.027 | 0.0034 | 0.0007 |
| 2 | hsa-miR-185-3p | 4.449 | 0.046 | 0.0021 | 0.0008 |
| 3 | hsa-miR-526b-5p | 4.165 | 0.056 | 0.0046 | 0.0017 |
| 4 | hsa-miR-30b*-3p | 4.380 | 0.048 | 0.0042 | 0.0017 |
| 5 | hsa-miR-9-5p | 3.705 | 0.077 | 0.0051 | 0.0018 |
| 6 | hsa-miR-200a-3p | -3.585 | 11.999 | 0.0052 | 0.0019 |
| 7 | hsa-miR-886-5p | 4.305 | 0.051 | 0.0051 | 0.0024 |
| 8 | hsa-miR-520d-5p | 3.311 | 0.1011 | 0.0072 | 0.0031 |
| 9 | hsa-miR-654-5p | 3.101 | 0.117 | 0.0087 | 0.0038 |
| 10 | hsa-miR-493-3p | 3.086 | 0.118 | 0.0098 | 0.0043 |
| 11 | hsa-miR-933 | -3.849 | 14.414 | 0.0101 | 0.0047 |
| 12 | hsa-miR-663a | -4.294 | 19.621 | 0.0088 | 0.0051 |
| 13 | hsa-miR-873-5p | -2.886 | 7.392 | 0.0113 | 0.0053 |
| 14 | hsa-miR-377-3p | 2.875 | 0.136 | 0.0117 | 0.0064 |
| 15 | hsa-miR-510-5p | 2.961 | 0.128 | 0.0123 | 0.0075 |
| 16 | hsa-miR-95-3p | 2.7001 | 0.154 | 0.0179 | 0.0119 |
| 17 | hsa-miR-143-3p | -4.115 | 17.333 | 0.0190 | 0.0124 |
| 18 | hsa-miR-708-5p | 3.310 | 0.101 | 0.0231 | 0.0136 |
| 19 | hsa-miR-365a-3p | -4.525 | 23.020 | 0.0218 | 0.0150 |
| 20 | hsa-miR-202-3p | 2.465 | 0.181 | 0.0272 | 0.0232 |
| 21 | hsa-miR-452-5p | 2.680 | 0.156 | 0.0319 | 0.0248 |
| 22 | hsa-miR-490-3p | 2.880 | 0.136 | 0.0374 | 0.0299 |
| 23 | hsa-miR-760 | 3.536 | 0.086 | 0.0356 | 0.0336 |
| 24 | hsa-miR-376b-3p | 2.385 | 0.191 | 0.0450 | 0.0367 |
| 25 | hsa-miR-184 | 2.201 | 0.218 | 0.0448 | 0.0389 |
| 26 | hsa-miR-27b-3p | -1.916 | 3.774 | 0.0486 | 0.0414 |
| 27 | hsa-miR-362-5p | -2.235 | 4.708 | 0.0498 | 0.0438 |
| 28 | hsa-miR-382-5p | 1.9611 | 0.257 | 0.0489 | 0.0448 |
| 29 | hsa-miR-502-5p | 3.755 | 0.074 | 0.0496 | 0.0494 |
The 9 top affected cellular pathways influenced from the 15 microRNAs of the normal-mild comparison.
| BIOCARTA Term | Genes ID (ENTREZ) | Fold Enrichment | FDR p-value | |
|---|---|---|---|---|
| 1 | h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition | 595, 8517, 3265, 1869, 1019, 5058, 5925, 1026, 207, 1021, 898, 5295, 5594 | 3.8166215 | 3.49E-05 |
| 2 | h_arfPathway:Tumor Suppressor Arf Inhibits Ribosomal Biogenesis | 7291, 1869, 84172, 4193, 5925, 5294, 5295, 4609, 51082 | 3.963414634 | 7.69E-04 |
| 3 | h_igf1mtorPathway:Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway | 3480, 5728, 5515, 1978, 3636, 5295, 207, 6194, 2475 | 3.567073171 | 0.001766927 |
| 4 | h_cellcyclePathway:Cyclins and Cell Cycle Regulation | 595, 1021, 1869, 993, 894, 891, 1019, 5925, 1026, 898 | 3.170731707 | 0.002174754 |
| 5 | h_ctcfPathway:CTCF: First Multivalent Nuclear Factor | 5728, 5515, 4089, 7049, 4193, 7048, 5294, 5295, 4609, 2475 | 3.170731707 | 0.002174754 |
| 6 | h_erkPathway:Erk1/Erk2 Mapk Signaling pathway | 2872, 3480, 3265, 2782, 5156, 9252, 5515, 1956, 2002, 4609, 5594 | 2.906504065 | 0.002408948 |
| 7 | h_p53Pathway:p53 Signaling Pathway | 595, 1869, 596, 4193, 1019, 5925, 1026, 898 | 3.730272597 | 0.002850649 |
| 8 | h_telPathway:Telomeres, Telomerase, Cellular Aging, and Immortality | 3480, 596, 5515, 1956, 3845, 5925, 207, 4609 | 3.52303523 | 0.00417549 |
| 9 | h_tgfbPathway:TGF-beta signaling pathway | 4088, 4089, 6498, 7048, 6885, 9372, 4092, 4087 | 3.337612323 | 0.005919135 |
The 9 top affected cellular pathways influenced from the 29 microRNAs of the normal-severe comparison.
| BIOCARTA Term | Genes ID (ENTREZ) | Fold Enrichment | FDR p-value | |
|---|---|---|---|---|
| 1 | h_tnfr1Pathway:TNFR1 Signaling Pathway | 9530, 5599, 4214, 7124, 5058, 6885, 9731, 836, 4000, 4001, 835, 1676, 1677, 7186, 84823, 142 | 2.526724976 | 3.63E-04 |
| 2 | h_tgfbPathway:TGF-beta signaling pathway | 7040, 2033, 4088, 4089, 324, 6498, 7048, 6885, 9372, 4092, 999, 4087 | 2.992174313 | 4.54E-04 |
| 3 | h_g1Pathway:Cell Cycle: G1/S Check Point | 595, 7040, 1021, 993, 7027, 472, 4088, 2932, 1017, 4089, 1027, 1026, 898, 7157, 983 | 2.368804665 | 0.001372642 |
| 4 | h_cellcyclePathway:Cyclins and Cell Cycle Regulation | 595, 7027, 1017, 1027, 1026, 983, 1021, 993, 894, 5933, 891, 898, 896 | 2.463556851 | 0.002255077 |
| 5 | h_il2rbPathway:IL-2 Receptor Beta Chain in T cell Activation | 3265, 596, 6464, 5478, 8651, 3716, 207, 6198, 1399, 2885, 3667, 6777, 9021, 2353, 22806, 4609, 5594 | 2.065111759 | 0.003326904 |
| 6 | h_mapkPathway:MAPKinase Signaling Pathway | 4149, 4209, 3265, 5599, 1432, 8550, 6464, 2872, 7040, 7186, 4214, 673, 9252, 4215, 4293, 5058, 6885, 1326, 1385, 6667, 6197, 6198, 2885, 5597, 4790, 2353, 5598, 5879, 4609, 5594 | 1.633658389 | 0.004199785 |
| 7 | h_nfatPathway:NFAT and Hypertrophy of the heart (Transcription in the broken heart) | 811, 3265, 2147, 5599, 805, 58, 9421, 1432, 801, 4775, 2932, 207, 5532, 1906, 4620, 6198, 5573, 808, 4773, 1482, 5594 | 1.842403628 | 0.004474806 |
| 8 | h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition | 595, 3265, 7027, 1017, 5058, 1027, 1026, 207, 1021, 4790, 898, 5879, 5594 | 2.281071159 | 0.00499535 |
| 9 | h_pyk2Pathway:Links between Pyk2 and Map Kinases | 3265, 805, 1399, 5599, 4214, 1432, 2885, 6464, 801, 808, 5058, 5879, 5594 | 2.199604332 | 0.007120062 |
The 9 top affected cellular pathways influenced from the 9 microRNAs of the mild-severe intersection.
| BIOCARTA Term | Genes ID (ENTREZ) | Fold Enrichment | FDR p-value | |
|---|---|---|---|---|
| 1 | h_telPathway:Telomeres, Telomerase, Cellular Aging, and Immortality | 3480, 596, 5515, 3845, 207, 4609 | 5.310457516 | 0.003759507 |
| 2 | h_raccycdPathway:Influence of Ras and Rho proteins on G1 to S Transition | 595, 3265, 5058, 1026, 898, 207, 5594 | 4.130355846 | 0.005046085 |
| 3 | h_igf1mtorPathway:Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway | 3480, 5728, 5515, 1978, 3636, 207 | 4.779411765 | 0.006156962 |
| 4 | h_erkPathway:Erk1/Erk2 Mapk Signaling pathway | 2872, 3480, 3265, 5156, 5515, 4609, 5594 | 3.717320261 | 0.008692161 |
| 5 | h_tnfr1Pathway:TNFR1 Signaling Pathway | 1677, 7124, 5058, 6885, 9731, 84823, 4001 | 3.717320261 | 0.008692161 |
| 6 | h_mitochondriaPathway:Role of Mitochondria in Apoptotic Signaling | 56616, 54205, 1677, 596, 331, 9731 | 4.344919786 | 0.00946723 |
| 7 | h_caspasePathway:Caspase Cascade in Apoptosis | 54205, 1677, 331, 9731, 84823, 4001 | 3.982843137 | 0.01383679 |
| 8 | h_mapkPathway:MAPKinase Signaling Pathway | 2872, 4209, 3265, 673, 8550, 5597, 5058, 6885, 5598, 6667, 4609, 5594 | 2.197430696 | 0.016110142 |
| 9 | h_p53Pathway:p53 Signaling Pathway | 595, 596, 4193, 1026, 898 | 4.685697809 | 0.017859453 |
Fig 5Validation of miR-143-3p expression.
(A) Increased expression of miR-143-3p in either 'mild' and 'severe' group. miR-143-3p expression was up-regulated in both mild and severe groups with a fold change of 3.9 and 7.0 respectively (p = 0.005 and p = 0.1*10−6). The graph shows the mean values of all validated patients. The number of patients in the individual validation is slightly different from the number of patients in the pool samples. On the y axis the fold change is denoted. The star on top of the horizontal brackets indicate a significant difference. n is giving the sample number of all individually validated patients. The standard deviation is given by the top indicators. (B) The receiver-operator characteristic curve for miR-143-3p suggests this microRNA for being a suitable biomarker. miR-143-3p is able to discriminate SMV patients from control samples by an AUC of 0.87 (p = 0.0004). The x and y axis denote the percentage values of the performance parameters 'specificity' and 'sensitivity' over the full range from 0 to 100 percent.
Fig 6Graphical abstract.